EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.302
https://www.valueinhealthjournal.com/article/S1098-3015(22)02506-2/fulltext
Title :
EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02506-2&doi=10.1016/j.jval.2022.09.302
First page :
Section Title :
Open access? :
No
Section Order :
12108